67 completed. 67 Phase 2, 18 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 67 | Completed 67 |
| Phase 1 | 18 | Completed 18 |
| Phase 3 | 4 | Completed 4 |
Follow rapamycin: new trials by email Literature Review of rapamycin trials Research Report on rapamycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography Sirolimus - Alzheimer Disease | Phase 1 / Phase 2 | Completed | Karolinska Institutet | 14 | 2023-09-01 | 2025-07-03 |
| Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome low-dose interleukin-2, rapamycin - Sjögren's Syndrome | Phase 1 / Phase 2 | Completed | Peking University People's Hospital | 30 | 2022-12-05 | 2024-07-09 |
| REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept Study Sirolimus 0.5Mg Tab, 1st MRI scan, 1st Percutaneous or Endoscopic Ultrasound guided liver biopsy - Advanced Chronic Liver Disease | Phase 2 | Completed | Nottingham University Hospitals NHS Trust | 41 | 2022-07-25 | 2024-10-01 |
| Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma. Sirolimus - Kaposiform Hemangioendothelioma | Phase 2 | Completed | West China Hospital | 79 | 2021-02-17 | 2024-05-07 |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation Fludarabine, Itacitinib Adipate, Melphalan - Acute Leukemia, Hematologic and Lymphocytic Disorder | Phase 2 | Completed | City of Hope Medical Center | 59 | 2020-11-11 | 2026-03-30 |
| Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia Sirolimus, Placebo - COVID-19 | Phase 2 | Completed | University of Cincinnati | 32 | 2020-04-24 | 2024-04-05 |
| Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study Rapamycin, Placebo - Aging | Phase 2 | Completed | AgelessRx | 129 | 2020-01-01 | 2024-01-24 |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Selumetinib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1 | Phase 2 | Completed | Sarcoma Alliance for Research through Collaboration | 21 | 2019-10-02 | 2026-05-27 |
| Sirolimus for Cowden Syndrome With Colon Polyposis Sirolimus - PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome | Phase 2 | Completed | Ohio State University | 5 | 2019-09-16 | 2025-06-10 |
| Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex rapamycin, placebo - Facial Angiofibroma, Tuberous Sclerosis | Phase 2 / Phase 3 | Completed | Dermatology Specialties Limited Partnership | 107 | 2019-07-28 | 2023-09-08 |
| Enhancing Self Regulation Among Smokers sirolimus, Placebo - Smoking Cessation, Smoking, Cigarette | Phase 2 | Completed | Medical University of South Carolina | 22 | 2018-10-01 | 2021-03-09 |
| Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial Sirolimus, Resveratrol - Lymphangioleiomyomatosis | Phase 2 | Completed | University of Cincinnati | 25 | 2018-03-31 | 2023-02-01 |
| Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome Rapamycin - Activated PI3K-delta Syndrome, Immunodeficiency Primary | Phase 1 / Phase 2 | Completed | Children's Hospital of Fudan University | 30 | 2017-12-01 | 2024-07-09 |
| Novel Compositions for Treating or Preventing Dermal Disorders Rapamycin - Dermal Atrophy | Phase 1 / Phase 2 | Completed | Drexel University | 36 | 2017-09-25 | 2021-09-22 |
| Rapamycin Treatment for ALS Rapamycin, Placebo Oral Tablet - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Azienda Ospedaliero-Universitaria di Modena | 63 | 2017-09-19 | 2024-09-19 |
| Immunomodulatory Effects of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation Failure Rapamycin - Recurrent Implantation Failure | Phase 2 | Completed | Mehdi Yousefi | 121 | 2017-07-11 | 2019-04-10 |
| Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma Sirolimus, Prednisolone - Kaposiform Hemangioendothelioma, Kasabach Merritt Phenomenon | Phase 2 | Completed | West China Hospital | 30 | 2017-06-01 | 2022-04-21 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Fludarabine, Cyclophosphamide, MMF - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 15 | 2017-05-15 | 2025-07-04 |
| Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome Sirolimus - Sturge-Weber Syndrome | Phase 2 / Phase 3 | Completed | Anne Comi, MD | 10 | 2017-01-01 | 2021-11-01 |
| HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1 - Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Completed | Center for International Blood and Marrow Transplant Research | 80 | 2016-12-01 | 2025-08-06 |
Showing 20 of 67. Sign in to see all of them.
Leukemia, Myeloid, Acute (8) · Leukemia (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, Non-Hodgkin (5) · Myelodysplastic Syndromes (5) · Lymphoma (4) · Lymphoma, Mantle-Cell (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Diabetes Mellitus, Type 1 (3) · Hodgkin Disease (3) · Lymphoma, Large B-Cell, Diffuse (3) · Multiple Myeloma (3) · Neoplasms (3) · Tuberous Sclerosis (3) · Congenital Abnormalities (2)
Masonic Cancer Center, University of Minnesota (3) · National Eye Institute (NEI) (3) · Children's Hospital of Philadelphia (2) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · Sarcoma Alliance for Research through Collaboration (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · University of Cincinnati (2) · University of Regensburg (2) · University of Washington (2) · West China Hospital (2) · AgelessRx (1) · Allan D Kirk, MD, PhD (1) · Anne Comi, MD (1) · Azienda Ospedaliero-Universitaria di Modena (1)
United States (49) · Italy (5) · China (4) · Germany (3) · Australia (2) · France (2) · Spain (2) · Sweden (2) · Canada (1) · Czechia (1) · Denmark (1) · Hungary (1) · Iran (1) · Israel (1) · Netherlands (1)
AeRang Kim, MD, PhD (2) · Brigitte Widemann, MD (2) · Emanuele Bosi, MD (2) · Lorenzo Piemonti, MD (2) · Margaret Kasner, MD (2) · Nishant Gupta, MD (2) · Yi Ji, MD, PhD (2) · Aaron R Weiss, DO (1) · Aldo T Iacono, MD (1) · Anne M Comi, M.D. (1) · Anthony Jevnikar, MSc MD (1) · Antonio Dal Canton, MD (1) · Antonio Guasch, MD (1) · Brenda Sandmaier (1) · Brian Weiss, MD (1)
PMID 12176626, PMID 12176628, PMID 15233820, PMID 17510057, PMID 18215105, PMID 18997171, PMID 19167681, PMID 19208097, PMID 19710204, PMID 19950289, PMID 20664591, PMID 21314851, PMID 21403127, PMID 21514552, PMID 21552302, PMID 21915260, PMID 22052056, PMID 22430088, PMID 22889462, PMID 22946986, PMID 23437092, PMID 23548622, PMID 23796341, PMID 24684552, PMID 24762139, PMID 25394810, PMID 25525171, PMID 25526946, PMID 25965838, PMID 26009261, PMID 26436448, PMID 26504182, PMID 28486787, PMID 29136317, PMID 29388191, PMID 29551338, PMID 29800048, PMID 30396415, PMID 30672136, PMID 31030813, PMID 31489702, PMID 31738834, PMID 31761958, PMID 32014025, PMID 32089640, PMID 32603426, PMID 33124663, PMID 33297779, PMID 33905264, PMID 33942491
P30CA015704 (3), 2023 (1), P01CA018029 (1), P01CA030206 (1), P30CA006516 (1), P30CA006973 (1), R01CA107164 (1), R34HL138235 (1), U10CA021115 (1), U10HL069294 (1), U24CA076518 (1), U54NS065705 (1)